舌下神经刺激治疗唐氏综合征合并阻塞性睡眠呼吸暂停患儿的更新研究
本研究为病例系列,纳入20例10-21岁唐氏综合征合并重度OSA且既往腺样体扁桃体切除术后仍存在的非肥胖儿童及青少年,均CPAP治疗失败并经睡眠内镜确认手术适应症。主要评估安全性与不良事件,次要结局包括AHI降低百分比、治疗依从性及OSA-18生活质量变化。结果显示舌下神经刺激安全有效,无长期并发症,2例间歇不良事件经修正手术纠正,滴定AHI中位降低85%,每晚中位使用9.21小时,OSA-18中位变化1.15提示中度但显著的临床改善。
要点
- 舌下神经刺激在研究人群中安全有效,2例轻微手术并发症经手术纠正。
- 20例患儿完成2个月多导睡眠监测,滴定AHI中位降低85%(IQR 75%-92%)。
- 每晚中位使用9.21小时,OSA-18评分中位变化1.15,提示中度但显著的临床改善。
核心结论
- 舌下神经刺激在研究人群中安全有效,2例轻微手术并发症经手术纠正。
- 总体数据提示儿童舌下神经刺激似乎是唐氏综合征合并难治性重度OSA患儿的安全有效疗法。
研究设计与样本
- 病例系列研究,纳入20例10-21岁唐氏综合征合并重度OSA(AHI>10且<50次/小时)的非肥胖儿童及青少年,既往腺样体扁桃体切除术后仍存在OSA。
- 参与者CPAP治疗试验失败,并经睡眠内镜确认手术适应症。
- 主要结局为评估安全性并监测不良事件,次要结局包括AHI降低百分比、治疗依从性及OSA-18生活质量问卷变化。
主要发现
- 全部20例儿童(中位年龄16.0岁,四分位距13-17岁,13例男性)均植入成功,无长期并发症。
- 报告2例间歇不良事件,均经修正手术纠正。
- 20例参与者完成2个月多导睡眠监测,滴定AHI中位降低85%(四分位距75%-92%)。
- 这些儿童每晚中位使用时间为9.21小时。
- OSA-18评分中位变化为1.15,提示中度但显著的临床变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 证据等级为4级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: Hypoglossal nerve (HGN) stimulation is a novel therapy for obstructive sleep apnea (OSA) in adults. Its efficacy and safety in children with Down syndrome (DS) was previously reported in a preliminary case series of six adolescents. STUDY DESIGN: Case series. METHODS: Twenty nonobese children and adolescents (aged 10-21 years) with DS and severe OSA (apnea-hypopnea index [AHI] >10 and <50 events/hr) despite prior adenotonsillectomy were enrolled. Participants had failed a trial of continuous positive airway pressure therapy and underwent sleep endoscopy confirming surgical candidacy. The primary outcome was to assess safety and monitor for adverse events. Secondary outcomes included efficacy in reducing AHI (% reduction in AHI), adherence to therapy, and change in a validated quality-of-life instrument, the OSA-18 survey. RESULTS: All 20 children (median age = 16.0 years [interquartile range = 13-17 years], 13 male) were implanted with no long-term complications. We report two interval adverse events, both of which were corrected with revision surgery. Twenty participants completed the 2-month polysomnogram, with median percent reduction in titration AHI of 85% (interquartile range = 75%-92%). The median nightly usage for these children was 9.21 hours/night. There was a median change in the OSA-18 score of 1.15, indicating a moderate, yet significant, clinical change. CONCLUSIONS: HGN stimulation was safe and effective in the study population. Two minor surgical complications were corrected surgically. Overall, these data suggest that pediatric HGN stimulation appears to be a safe and effective therapy for children with DS and refractory severe OSA. LEVEL OF EVIDENCE: 4 Laryngoscope, 130:E263-E267, 2020.
引用
- Caloway CL, Diercks GR, Keamy D, et al. Update on hypoglossal nerve stimulation in children with down syndrome and obstructive sleep apnea. Laryngoscope. 2019. PMID: 31219619. doi:10.1002/lary.28138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。